Guardant Health (NASDAQ:GH) is a company that specializes in precision oncology, focusing on blood tests for cancer detection and treatment. The company is a key player in the healthcare sector, competing with other firms in the field of cancer diagnostics. On February 23, 2026, Raymond James updated its rating for Guardant Health to "Outperform," with the stock priced at $101.49. The price target was also raised from $115 to $129.
Despite this positive outlook from Raymond James, Granite Investment Partners LLC has significantly reduced its stake in Guardant Health by 52.1%, now holding 185,301 shares. This reduction represents 0.15% of Guardant Health, valued at approximately $11.6 million. This move contrasts with other major investors who have adjusted their positions in Guardant Health.
Norges Bank has acquired a new stake in Guardant Health worth around $64.1 million during the second quarter. Meanwhile, Franklin Resources Inc. increased its investment by 78.2%, now holding 2,319,947 shares valued at $120.7 million after purchasing an additional 1,018,144 shares. Invesco Ltd. also expanded its holdings by 27.3% during the undefined quarter.
The current stock price for GH is approximately $100.42, reflecting a decrease of about 2.60%. The stock has dropped by $2.68 today, with fluctuations between a low of $100.29 and a high of $103.58. Over the past year, the stock has reached a high of $120.74 and a low of $34.88. GH has a market capitalization of approximately $13.04 billion, with a trading volume of around 274,345 shares.
